RE:RE:RE:RE:RE:stop bittchingI believe the BOD wears some of this. Surely they could have forseen the potential for delays and its effect on the runway to revenue and brought better oversight. Things will turn out, especially considering the back stopping of the plasma derived therapeutic division, but does it really have to be this painful. A more modest, prudent rollout would have served us better.
No one disputes the fact, more money was going to be needed and that placements were going to happen. Better execution would have meant doing so at higher levels on a better trend line.
Good luck,
Felco